Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Shorter Radiation Treatment for Localised Prostate Cancer

Tests a shorter course of high-dose radiation in adults with localised prostate cancer.

Key facts

Who runs it
University Hospital Schleswig-Holstein
Where
Erfurt, Frankfurt am Main, Kiel, and Munich, GermanySee the 6 sites
Trial code
Registry title
Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)
Status
Recruiting
People taking part
175 people, planned
Started
10 Dec 2025
Expected to end
31 Dec 2029
Type of study
Interventional
Treatments tested
  • Hypofractionated Radiosurgery
Record updated
29 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has not spread outside the prostate. They would receive radiosurgery (focused radiation) in 3 sessions.

Age
18 years or older
Sex
Men only
Disease stage
Prostate cancer confirmed by tissue test, still inside the prostate (cT1-T2c N0 M0). Gleason grade 7 or lower, ISUP Grade Group 1-3. PSA below 20 ng/ml. Prostate volume below 80 cm³. IPSS score 12 or lower.
Earlier treatment
People who had radiotherapy to the pelvis before cannot join. People who had a transurethral resection, laser enucleation or prostate ablation before cannot join.

Main reasons for not taking part

  • Earlier radiotherapy to the pelvis
  • Earlier transurethral resection, laser enucleation or prostate ablation
  • Cannot have an MRI or fiducial marker implantation (for example gold allergy)
  • Other illness thought to harm treatment compliance
  • Legal incapacity or no informed consent

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Localised, histopathologically confirmed Prostate Cancer (cT1-T2c N0 M0)
  • Gleason-grade ≤7, ISUP Grade Group 1-3
  • Guideline-based staging
  • Age ≥ 18 years
  • PSA < 20 ng/ml
  • Volume of the prostate < 80 cm³
  • IPSS-Score ≤ 12
  • Written informed consent

Who cannot take part

  • History of prior pelvic radiotherapy
  • Previous transurethral resection, laser enucleation or prostate ablation
  • Contraindication to MRI or Fiducial marker implantation (e.g. gold allergy)
  • Relevant comorbidity thought to adversely affect treatment compliance
  • Legal incapacity or lack of informed consent

Where in Germany

  • CyberKnife Centrum MitteldeutschlandErfurt, GermanyContact: Hans-Ulrich Herold, MDTaking people
  • Saphir Radiosurgery Center Frankfurt am MainFrankfurt am Main, GermanyContact: Christian Arnold, MDTaking people
  • University Hospital FrankfurtFrankfurt am Main, GermanyContact: Oliver Blanck, PhDNo longer taking part
  • University Medical Center Schleswig-HolsteinKiel, GermanyContact: Stefan Huttenlocher, MDTaking people
  • Saphir Radiosurgery Center Norther GermanyKiel, GermanyContact: Oliver Blanck, PhDNo longer taking part
  • European Radiosurgery Center MunichMunich, GermanyContact: Alexander Muacevic, MDTaking people

About the trial

What the trial wants to find out

Hypofractionated radiosurgery with 5 fractions is considered standard of care for localized prostate cancer. The investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 3 fractions in patients with localised prostate cancer under the hypothesis that the ratio of patients with late GU and GI toxicity ≥ grade 2 after 1 year amounts to 8.4% and 1.3% and is significant lower than 16.4% and 5.7% currently.

The group in the trial

  • Hypofractionated RadiosurgeryTreatment being tested

    3 fractions with 9.5-10.5 Gy, total dose 28.5-31.5 Gy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)
Plain-language title
Shorter Radiation Treatment for Localised Prostate CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 April 2026